Vesnarinone: a differentiation-inducing anti-cancer drug

Anticancer Drugs. 2003 Jul;14(6):391-5. doi: 10.1097/00001813-200307000-00001.

Abstract

Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies, including leukemia and several solid tumors. Furthermore, vesnarinone potentiates the effect of conventional cytotoxic chemotherapy or radiation therapy. Combination of differentiation-inducing therapy by vesnarinone with conventional chemotherapy or radiation therapy might be second- or third-line therapy in patients with advanced cancer. Analysis of the molecular mechanisms of the tumor differentiation therapy by vesnarinone might provide selective and targeted molecules for novel tumor dormancy therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Humans
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / radiotherapy
  • Pyrazines
  • Quinolines / chemistry
  • Quinolines / therapeutic use*
  • Repressor Proteins / genetics
  • Repressor Proteins / isolation & purification

Substances

  • Antineoplastic Agents
  • Pyrazines
  • Quinolines
  • Repressor Proteins
  • TSC22D1 protein, human
  • Tgfb1i4 protein, mouse
  • vesnarinone